Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating

Journal of Neuroscience

Volumn 21, Issue 2, 2001, Pages 601-608

  Binder, Elisabeth B ^a   Kinkead, Becky ^b   Owens, Michael J ^b   Kilts, Clinton D ^b   Nemeroff, Charles B ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Haloperidol; Isolation rearing; Latent inhibition; Prepulse inhibition; Quetiapine; SR 142948A

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTENSIN; QUETIAPINE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; FEMALE; LATENT INHIBITION; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

EID: 0035863237     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-02-00601.2001     Document Type: Article

References (57)

1. The neuropathology of schizophrenia
2. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine
3. Differential performance of acute and chronic schizophrenics in a latent inhibition task
4. Ontogeny of brain neurotensin in the rat: A radioimmunoassay study
5. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
6. CSF concentrations of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates
7. Neurotensin increases extracellular striatal dopamine levels in vivo
8. Haloperidol enhancement of latent inhibition: Relation to therapeutic action?
9. Autoradiographic localization of muopioid and neurotensin receptors within the mesolimbic dopamine system
10. Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action
11. Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release: A dualprobe microdialysis study in the awake rat
12. Elementary neuronal dysfunctions in schizophrenia
13. Receptor-receptor interactions and their relevance for receptor diversity: Focus on neuropeptide/dopamine interactions
14. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients
15. Startle habituation and sensorimotor gating in schizophrenia and related animal models
16. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia
17. Regional studies of catccholamines in the rat brain
18. Latent inhibition in drug naive schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPET
19. Increased distractability in schizophrenic patients
20. Startle gating deficits occur across prepulse intensities in schizophrenic patients
21. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensm receptor
22. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist
23. Isolation rearing in rats: Pre- and postsynaptic changes in striatal dopaminergic systems
24. A simple (or simplistic?) cognitive model for schizophrenia
25. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems
26. Neurotensin and the scrotonergic system
27. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system
28. Does neurotensin mediate the effects of antipsychotic drugs?
29. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain
30. Normalization of information processing deficits in schizophrenia with clozapine
31. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system
32. The neurotensin receptor: Is there more than one subtype?
33. Reduced CSF neurotensin concentration in drug-free schizophrenic patients
34. Latent inhibition in humans: Data, theory, and implications for schizophrenia
35. Latent inhibition: The effect of non reinforced pre-exposure to the conditioned stimulus
36. Latent inhibition and schizophrenia
37. Disorders of attention and perception in early schizophrenia
38. Neurotensin: Perchance an endogenous neuroleptic?
39. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome
40. The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: An in vivo microdialysis study
41. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients
42. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions
43. Use of nonpeptide antagonists to explore the physiological roles of neurotensin: Focus on brain neurotensin/dopamine interactions
44. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorders
45. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes
46. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
47. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
48. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens
49. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs
50. Psychphysiological aspects of schizophrenia
51. Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain
52. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: A search for a common ground
53. The switching model of latent inhibition: An update of neural substrates
54. The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine
55. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment
56. Social isolation in the rat produces developmentally specific deficits in prepulse inhibition of the acoustic startle response without disrupting latent inhibition
57. The new antipsychotic compounds: Is a clinical choice algorithm possible?